|
Leading Independent Research and Consulting Company Focused on Peripheral Artery Disease (PAD)
and Critical Limb Ischemia (CLI)
Consulting Expertise
|
|
Diseases
|
Therapies
|
Economics
|
Knowledge & Awareness
|
|
Peripheral Artery Disease
PAD
|
Chronic Total Occlusions
|
Macro Costs
|
Physician
|
|
Critical Limb Ischemia
CLI
|
Thrombus Removal
Thrombolytics
|
Cost-Effectiveness
|
Consumer
|
|
Intermittent Claudication
IC
|
Anticoagulants
|
Outcomes
|
|
|
Asymptomatic Disease
|
Antiplatelets
|
Competitive Product Analysis
|
|
|
Acute Limb Ischemia
ALI
|
Balloon Angioplasty
|
Technology Assessment
|
|
|
Diabetic Foot Ulcer DFU
|
Atherectomy
|
Coding
|
|
|
Peripheral Neuropathy
|
Stents
|
Reimbursement
|
|
|
Buerger’s Disease
|
Peripheral Bypass
|
|
|
|
|
Angiogenesis/Biotechnology
|
|
|
|
|
Stem Cells
|
|
|
|
United States
|
Europe
|
|
Canada
|
Middle East
|
|
Latin America
|
China
|
|
India
|
Asia
|
|
|
|
PRICING & SAMPLE PROJECTS
PROPRIETARY RESEARCH DATABASES
|
THE SAGE GROUP Research:
The prevalence of peripheral artery disease (PAD) in the U.S. is much higher than the commonly cited figures of 8-12 million.
According to THE SAGE GROUP, 18 million people in the U.S. had PAD in 2010. With the ageing population, this number is projected to exceed 21 million by 2020.
|
